Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

Credit: NCI/Linda BartlettIn an oral history conducted by FDA in September 2013, Andrew C. von Eschenbach recounted his eight-month stint in a dual role as both FDA acting commissioner and NCI director.

CRUK and partners pledge £5.5m funding for colorectal cancer research

Cancer Research UK and partners on March 31 committed £5.5 million in funding to form a research team tasked with making personalized medicine a reality for people with colorectal cancer. The initiative is designed to unite research expertise and solve unanswered questions about the disease.

April 04, 2025

Vol.51 No.13

In Brief

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

University Hospitals Cleveland Medical Center has announced a collaboration with global healthcare AI company Qure.ai to deploy chest X-ray AI supporting earlier identification of lung cancers.

April 04, 2025

Vol.51 No.13

Drugs & Targets

FDA approves durvalumab for muscle invasive bladder cancer

FDA approved AstraZeneca’s durvalumab (Imfinzi) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant treatment following radical cystectomy, for adults with muscle invasive bladder cancer.

April 04, 2025

Vol.51 No.13

Capitol Hill

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

The U.S. Department of Health and Human Services announced that it is making sweeping revisions by cutting personnel, centralizing functions, and consolidating divisions.

March 28, 2025

Vol.51 No.12

By Claire Marie Porter and Jacquelyn Cobb

News Analysis

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

The March 15 continuing resolution has gutted the Department of Defense Congressionally Directed Medical Research Program. The program’s funding was cut by 57%, compared to Fiscal Year 2024 levels—from $1.5 billion to $650 million.

March 28, 2025

Vol.51 No.12

By Jacquelyn Cobb

Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president

YOU MAY BE INTERESTED IN

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

CRUK and partners pledge £5.5m funding for colorectal cancer research

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

FDA approves durvalumab for muscle invasive bladder cancer

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated

Renew today!

Subscriber content

Never miss an issue!

Login

Former CDER Director Patrizia Cavazzoni named Pfizer chief medical officer, executive vice president

YOU MAY BE INTERESTED IN

In an oral history now taken down by FDA, Andrew von Eschenbach recounts his stint as the head of both FDA and NCI—simultaneously

CRUK and partners pledge £5.5m funding for colorectal cancer research

University Hospitals Cleveland, Qure.ai collaborate on early lung cancer detection

FDA approves durvalumab for muscle invasive bladder cancer

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hitAlso this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolutionPancreatic, lung, kidney cancer research programs eliminated

Never miss an issue!

Login

Kennedy announces massive cuts, centralization at HHS—NCI and FDA hit
Also this week: Columbia yields, Makary and Bhattacharya confirmed, tariffs on pharmaceuticals, and more changes impacting oncology

DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated